secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001104659-23-059817
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics Q1 net loss widens to $24.6M; cash post-merger $139M
-------------------------------------------------------------------------

- Net loss of $24.6M in Q1 2023, vs $11.3M in Q1 2022, driven by higher R&D and G&A expenses.
- Cash, cash equivalents and marketable securities of $139.0M as of March 31, 2023, vs $52.0M at Dec 31, 2022.
- Merger with Sesen Bio closed; net assets acquired $80.3M, concurrent financing raised $30.6M.
- Initiated Phase 1 sub-study of CT-0508 + KEYTRUDA; IND for CT-0525 expected H2 2023.
- R&D expenses $16.6M (up from $8.8M) and G&A expenses $9.6M (up from $2.2M) vs prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/0001104659-23-059817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923059817/tm2315501d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer